BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 25248688)

  • 1. Underestimation of unfractionated heparin therapy assessment due to platelet activation when using partial-draw (pediatric) citrate collection tubes.
    Desconclois C; Eschwège V; Proulle V; Boutekedjiret T; Dreyfus M; Toulon P
    Thromb Res; 2014 Nov; 134(5):1117-22. PubMed ID: 25248688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new plastic collection tube made of polyethylene terephtalate is suitable for monitoring traditional anticoagulant therapy (oral anticoagulant, unfractionated heparin, and low molecular weight heparin).
    Toulon P; Ajzenberg N; Smahi M; Guillin MC
    Thromb Res; 2007; 119(2):135-43. PubMed ID: 16426667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Theophylline adenosine dipyridamole (CTAD) and citrate evaluation to survey unfractionated heparin treatment: a delayed centrifugation validation for anti-Xa measurement?].
    Billoir P; Clavier T; Guilbert A; Barbay V; Chrétien MH; Fresel M; Abriou C; Girault C; Le Cam Duchez V
    Ann Biol Clin (Paris); 2020 Feb; 78(1):27-34. PubMed ID: 32108577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A low volume specimen container suitable for monitoring the aPTT of heparinized patients.
    Ray MJ; Carroll PA; Just SJ; Hawson GA
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):805-7. PubMed ID: 8292732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring treatments with unfractionated heparin: CTAD must be used instead of citrate as the anticoagulant solution when using partial-draw collection tubes. Results of a multicenter evaluation.
    Toulon P; Abecassis L; Smahi M; Ternisien C
    Thromb Res; 2010 Dec; 126(6):536-42. PubMed ID: 20950840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter evaluation of a bilayer polymer blood collection tube for coagulation testing: effect on routine hemostasis test results and on plasma levels of coagulation activation markers.
    Toulon P; Aillaud MF; Arnoux D; Boissier E; Borg JY; Gourmel C
    Blood Coagul Fibrinolysis; 2006 Nov; 17(8):625-31. PubMed ID: 17102648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is citrate theophylline adenosine dipyridamole (CTAD) better than citrate to survey unfractionated heparin treatment? Has delayed centrifugation a real impact on this survey?
    Billoir P; Clavier T; Guilbert A; Barbay V; Chrétien MH; Fresel M; Abriou C; Girault C; Le Cam Duchez V
    J Thromb Thrombolysis; 2019 Aug; 48(2):277-283. PubMed ID: 31098816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of pre-analytical variables on the anti-activated factor X chromogenic assay when monitoring unfractionated heparin and low molecular weight heparin anticoagulation.
    McGlasson DL; Kaczor DA; Krasuski RA; Campbell CL; Kostur MR; Adinaro JT
    Blood Coagul Fibrinolysis; 2005 Apr; 16(3):173-6. PubMed ID: 15795534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring heparin therapy: stability of two different anti-Xa assays using blood samples collected in citrate-containing and CTAD tubes.
    Gremillet M; Talon L; Lebreton A; Sinegre T
    Thromb J; 2023 Feb; 21(1):21. PubMed ID: 36803983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of evacuated collection tube fill volume and mixing on routine coagulation testing using 2.5-ml (pediatric) tubes.
    Chuang J; Sadler MA; Witt DM
    Chest; 2004 Oct; 126(4):1262-6. PubMed ID: 15486391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
    Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
    Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of different anticoagulant associations on haemostasis and biochemical analyses in feline blood specimens.
    Granat F; Monzali C; Jeunesse E; Guerlin M; Trumel C; Geffré A; Bourgès-Abella N
    J Feline Med Surg; 2017 Apr; 19(4):394-402. PubMed ID: 26887655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The study of anticoagulants selection in platelet-rich plasma preparation].
    Hua L; Lai G; Zhenjun L; Guie M
    Zhonghua Zheng Xing Wai Ke Za Zhi; 2015 Jul; 31(4):295-300. PubMed ID: 26665933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of platelet activation in several different anticoagulants by the Advia 120 Hematology System, fluorescence flow cytometry, and electron microscopy.
    Ahnadi CE; Sabrinah Chapman E; Lépine M; Okrongly D; Pujol-Moix N; Hernández A; Boughrassa F; Grant AM
    Thromb Haemost; 2003 Nov; 90(5):940-8. PubMed ID: 14597991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring heparin therapy by the activated partial thromboplastin time--the effect of pre-analytical conditions.
    van den Besselaar AM; Meeuwisse-Braun J; Jansen-Grüter R; Bertina RM
    Thromb Haemost; 1987 Apr; 57(2):226-31. PubMed ID: 3603414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings.
    Greinacher A; Alban S; Omer-Adam MA; Weitschies W; Warkentin TE
    Thromb Res; 2008; 122(2):211-20. PubMed ID: 18262226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring heparin therapy: APTT results from partial- vs full-draw tubes.
    Siegel JE; Bernard DW; Swami VK; Sazama K
    Am J Clin Pathol; 1998 Aug; 110(2):184-7. PubMed ID: 9704617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of CTAD (citrate-theophylline-adenosine-dipyridamole) as a universal anticoagulant in dogs.
    Granat FA; Geffré A; Lucarelli LA; Braun JD; Trumel C; Bourgès-Abella NH
    J Vet Diagn Invest; 2017 Sep; 29(5):676-682. PubMed ID: 28673194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticoagulation monitoring part 2: Unfractionated heparin and low-molecular-weight heparin.
    Spinler SA; Wittkowsky AK; Nutescu EA; Smythe MA
    Ann Pharmacother; 2005; 39(7-8):1275-85. PubMed ID: 15956240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unsuitability of evacuated tubes for monitoring heparin therapy by activated partial thromboplastin time.
    Heyns AD; van den Berg DJ; Kleynhans PH; du Toit PW
    J Clin Pathol; 1981 Jan; 34(1):63-8. PubMed ID: 7462439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.